Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Preclinical News

Cardior eyes heart failure cure with miRNA inhibitor

Hongjiang Li, Staff Writer
February 1, 2020 2:06 AM UTC
Updated on Feb 1, 2020 at 2:43 AM UTC

Cardior unveiled data on Friday that demonstrates its first clinical candidate goes beyond treating the cardiovascular symptoms of heart failure to reversing established disease in animal models.

Cardior Pharmaceuticals GmbH, which spun out of Hannover Medical School in 2016, is developing non-coding RNA-based therapeutics and diagnostics for cardiovascular diseases. Its lead candidate is CDR132L, a locked nucleic acid (LNA) antisense oligonucleotide against miR-132 for heart failure...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Cardior Pharmaceuticals GmbH